Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BuLLSEYE
2024-512950-13-00Phase 4Authorised
- Sponsor
- Erasmus MC
- Start
- Sep 2024
- Modality
- Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ceftriaxone, ceftazidime, amoxicillin, clavulanic acid, cefuroxime and 5 more in sepsis, septic shock and bacterial disease (2 arms), sponsored by Erasmus MC. Primary endpoint: 28-day mortality. Planned start Sep 2024; status: authorised.
02
Drugs
ceftriaxoneceftazidimeamoxicillinclavulanic acidcefuroxime
03
Conditions
sepsisseptic shockbacterial disease
Beyond the preview
Go deeper on 2024-512950-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512950-13-00.